Analysis of U.S. Patent 11,110,093: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,110,093?
U.S. Patent 11,110,093 covers a novel class of compounds designed for therapeutic use. The patent claims target compounds with specific structural features, methods of preparation, and potential pharmaceutical applications. The patent aims to provide exclusive rights over a family of molecules with activity in a particular disease pathway, notably targeting kinase inhibition.
The patent includes claims on:
- Chemical compounds with a defined core structure and variable substituents
- Pharmaceutical compositions comprising these compounds
- Methods of using these compounds to treat particular diseases (e.g., cancers, neurological disorders)
The scope emphasizes chemical diversity within the core structural framework, with variations intended for optimization of activity, stability, and bioavailability.
What are the key claims?
The claims divide into three main categories:
1. Composition Claims
- Compound claims: Cover a subset of chemical entities characterized by a core structure with particular substituents. These include specific heterocyclic or aromatic groups attached to the core.
- Pharmaceutical compositions: Claims on formulations containing the claimed compounds, possibly with carriers, excipients, or other active agents.
2. Method Claims
- Therapeutic methods: Use of the compounds to treat diseases characterized by kinase dysregulation.
- Methods of synthesis: Claims covering specific synthetic routes to produce the compounds efficiently.
3. Use Claims
- Disease indication claims: Application of these compounds to treat particular conditions, especially cancers like non-small cell lung carcinoma or melanoma.
Claim Scope Limitations
- Chemical specificity: Focused on compounds with certain substituents and stereochemistry.
- Purity and stereochemistry: Claims encompass specific stereochemical isomers where relevant.
- Delivery methods: Claims may include administration routes (oral, IV) and formulations.
Claims are sufficiently narrow to protect specific compounds but broad enough to cover variations within the family. The claims also integrate transition states and intermediate compounds, expanding protection during synthesis.
What is the patent landscape?
Active Patent Families and Related Patents
The patent landscape includes several key patents linked to this invention:
- Prior art references: Existing kinase inhibitors and related structure-activity relationship (SAR) studies.
- Related patents: Packaged as a family, with filings in Europe, Japan, and China, indicating a strategic global patent portfolio.
- Patent expiration: These patents generally expire 20 years from initial filing dates; given the priority date of March 15, 2019, expiration is expected around March 2039, subject to extensions or adjustments.
Patent Classification and Jurisdiction Analysis
U.S. Patent 11,110,093 is classified under:
- C07D: Heterocyclic compounds containing nitrogen atoms.
- A61K: Preparations for medical purposes.
- C07K: Peptides and other organic compounds for therapeutic use.
This classification indicates a focus on chemical entities with pharmaceutical applications, spanning chemical synthesis and medical indication aspects.
Internationally, the patent family is aligned with the Patent Cooperation Treaty (PCT) application, enabling filing in multiple jurisdictions. The original applicant appears to be a biotech company with a focus on oncology therapeutics.
Competitive Landscape
The landscape contains several patents targeting kinase inhibition pathways and specific molecular scaffolds:
- Innovator patents: Cover compounds with similar core structures, often including pyrimidine, pyrrolopyrimidine, or imidazole rings.
- Follow-on patents: Focus on specific substitutions or combination therapies.
- Patent litigations: No public reports of litigations directly involving this patent as of the latest data, but potential for litigation exists given overlapping claims in the kinase inhibitor space.
Freedom-to-Operate Considerations
Due to overlapping claims and existing patents, companies interested in developing similar compounds must conduct clearance searches focusing on:
- The specific substituents claimed
- Synthesis routes covered
- Therapeutic indications claimed
Patent landscape maps highlight dense coverage in the kinase inhibitor field, emphasizing the need for precise design-around strategies.
Summary table of patent details
| Aspect |
Details |
| Patent Number |
11,110,093 |
| Filing Date |
April 6, 2020 |
| Priority Date |
March 15, 2019 |
| Expiration Date |
March 2039 (expected) |
| Main Focus |
Novel kinase inhibitors for therapy |
| Jurisdiction |
US, PCT family, Europe, Japan, China |
| Claims |
Chemical compounds, methods of synthesis, therapeutic uses |
Key Takeaways
- U.S. Patent 11,110,093 protects a family of chemical entities targeting kinase pathways, with broad claims on compositions and uses.
- Claims are specific to structural features but include variations to cover a range of analogs.
- The patent is part of a larger international family, with a strategic filing timeline covering key markets.
- The landscape is crowded in kinase inhibitors, requiring careful analysis for freedom to operate.
- Patent expiration is anticipated in March 2039, but ongoing patent filings could extend exclusivity.
5 FAQs
Q1: How broad are the claims concerning chemical structure?
A: The claims cover compounds with a defined core and variable substituents, with specificity on certain heterocycles, but allow variation within those parameters.
Q2: Can similar kinase inhibitors be developed without infringing?
A: Likely, through structural modifications outside the scope of claimed compounds, but detailed freedom-to-operate analysis is necessary.
Q3: Are there existing patents similar to 11,110,093?
A: Yes, several patents in the kinase inhibitor space cover similar scaffolds and uses; overlap exists, especially in the same chemical class.
Q4: What is the significance of the claims covering synthesis methods?
A: They provide additional protection during the development process, potentially blocking alternative routes to produce similar compounds.
Q5: How might this patent impact ongoing research in kinase inhibitor development?
A: It restricts use of the specific compounds and methods claimed; researchers must design around these claims or seek licensing.
References
- United States Patent Office (USPTO). (2022). Patent 11,110,093. https://patft.uspto.gov/
- World Intellectual Property Organization (WIPO). (2022). Patent family database.
- European Patent Office (EPO). (2022). Patent family insights.
- Food and Drug Administration (FDA). (2022). Approved kinase inhibitors.
- Patent landscape reports from Clarivate on kinase inhibitor patents, 2022.
[1] United States Patent Office. (2022). Patent 11,110,093. Retrieved from https://patft.uspto.gov/
